Fertility and sterility · 2014
Anabolic steroid-induced hypogonadism: diagnosis and treatment.
СтатьяМетаанализОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rahnema Cyrus D, Lipshultz Larry I, Crosnoe Lindsey E, Kovac Jason R, Kim Edward D
Аннотация
OBJECTIVE: To develop an understanding of hypogonadal men with a history of anabolic-androgenic steroid (AAS) use and to outline recommendations for management.
DESIGN: Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria.
SETTING: Not applicable.
PATIENT(S): Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS.
INTERVENTION(S): History and physical examination followed by medical intervention if necessary.
MAIN OUTCOME MEASURES(S): Serum testosterone and gonadotropin levels, symptoms, and fertility restoration.
RESULT(S): Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators.
CONCLUSION(S): Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.
DESIGN: Review of published literature and expert opinions. Intended as a meta-analysis, but no quality studies met the inclusion criteria.
SETTING: Not applicable.
PATIENT(S): Men seeking treatment for symptomatic hypogonadism who have used nonprescribed AAS.
INTERVENTION(S): History and physical examination followed by medical intervention if necessary.
MAIN OUTCOME MEASURES(S): Serum testosterone and gonadotropin levels, symptoms, and fertility restoration.
RESULT(S): Symptomatic hypogonadism is a potential consequence of AAS use and may depend on dose, duration, and type of AAS used. Complete endocrine and metabolic assessment should be conducted. Management strategies for anabolic steroid-associated hypogonadism (ASIH) include judicious use of testosterone replacement therapy, hCG, and selective estrogen receptor modulators.
CONCLUSION(S): Although complications of AAS use are variable and patient specific, they can be successfully managed. Treatment of ASIH depends on the type and duration of AAS use. Specific details regarding a patient's AAS cycle are important in medical management.